Abstract
The rapid degradation and subsequent lack of efficacy of n-butyric acid in vivo has been improved by the synthesis of monosaccharide stable pro-drugs of butyric acid. We studied the effects of D1 (O-n-butanoyl-2,3-O-isopropylidene-alpha-D-mannofuranoside), G1 (1-O-n-butanoyl-D,L-xylitol), and F1 (1-O-n-butanoyl 2,3-O-isopropylidene-D,L-xylitol) on the maturation and proliferation of AML cell lines HL 60 and FLG 29.1 and of purified blast cells from 10 cases of de novo acute myeloid leukaemia (AML). AML cell maturation was measured by surface antigen expression, morphology and cytochemistry. Toxicology in mice was also evaluated (DL50 1000 mg/kg). In HL 60 cells G1 and D1 increased the expression of CD15 and CD11a (presenting 62% of promyelo-metamyelocytes), and in 7/10 cases of primary AMLs that of CD11a, CD11b, CD15, and myeloperoxidase. D1, G1 and F1 induced a dose-dependent inhibition of tritiated thymidine uptake. Apoptosis (evaluated by flow cytometry and agarose gel electrophoresis) was induced in AML blasts by D1 and F1 (79% and 94% respectively for HL 60 cells) and, with less effect, by G1 (27%). The persistence of maturative and apoptotic activity in these new pro-drugs of butyric acid, hydrolysed only inside the tumou...Continue Reading
References
Apr 1, 1978·Experimental Cell Research·T Shkolnik, L Sachs
Aug 4, 1977·Nature·M G RiggsV M Ingram
May 1, 1978·Proceedings of the National Academy of Sciences of the United States of America·S J CollinsR C Gallo
Mar 22, 1979·Nature·L C AnderssonC G Gahmberg
May 1, 1978·Cell·E P CandidoJ R Davie
Oct 15, 1976·Biochemical Pharmacology·F H Schneider
Nov 1, 1975·Cell·J G Rheinwald, H Green
Jul 1, 1975·Cell·A Leder, P Leder
Jan 1, 1992·The Journal of Cell Biology·V GatteiM L Brandi
Jun 19, 1992·International Journal of Cancer. Journal International Du Cancer·P PouillartC Chany
Jan 1, 1991·Leukemia Research·V SantiniB Löwenberg
Aug 19, 1991·International Journal of Cancer. Journal International Du Cancer·P PouillartC Chany
May 30, 1991·International Journal of Cancer. Journal International Du Cancer·P PlanchonD Brouty-Boyé
Mar 1, 1990·Clinical and Experimental Immunology·S J MartinT G Cotter
Mar 1, 1989·The Journal of Clinical Investigation·J S SavillC Haslett
Jan 1, 1988·Leukemia Research·M SalemB Löwenberg
Sep 1, 1987·European Journal of Cancer & Clinical Oncology·A A MillerC G Schmidt
Oct 29, 1987·Biochemical and Biophysical Research Communications·S P PerrineD V Faller
Oct 1, 1985·Annals of Internal Medicine·J M BennettC Sultan
Oct 1, 1981·In Vitro·R Van WijkJ Kruh
Jan 1, 1983·Cancer·A NovogrodskyR Zaizov
Apr 1, 1995·The Journal of Cell Biology·M L Hermiston, J I Gordon
Aug 1, 1993·The Journal of Experimental Medicine·R ManfrediniS Ferrari
Aug 31, 1993·Biochemical and Biophysical Research Communications·C CalabresseD Belpomme
Apr 25, 1996·Biochemical and Biophysical Research Communications·S T Chang, B Y Yung
May 1, 1997·Molecular and Cellular Biology·G L CondorelliC Peschle
Oct 6, 1997·The EMBO Journal·C T QuangJ Ghysdael
Jun 20, 1998·British Journal of Haematology·V SantiniP Rossi Ferrini
Dec 10, 1998·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·P PouillartP Villa
Citations
Oct 18, 2005·Annals of Hematology·Antonella Gozzini, Valeria Santini
Apr 7, 2005·Digestive Diseases and Sciences·Arkadiusz OrchelTadeusz Wilczok
Nov 17, 2001·Current Opinion in Pharmacology·E Garattini, M Terao
Sep 30, 1998·British Journal of Haematology·V Santini, P R Ferrini
Mar 21, 2003·Biology of Reproduction·Wei ShiValeri Zakhartchenko
Jun 7, 2000·Stem Cells·O Bruserud, B T Gjertsen
Nov 9, 2001·Leukemia & Lymphoma·V SantiniP Rossi Ferrini
Sep 23, 2003·Expert Opinion on Therapeutic Targets·Karl J TronstadØystein Bruserud
Jun 20, 1998·British Journal of Haematology·V SantiniP Rossi Ferrini
May 29, 2004·Anti-cancer Drugs·Loredana SerpeGian Paolo Zara
May 9, 2001·Blood·M S BoosalisS P Perrine
Dec 8, 2000·The Oncologist·O BruserudTs Huang
Jun 16, 2001·Hematology·WOLF-KARSTEN Hofmann, DIETER Hoelzer